Edition:
India

Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)

CRBP.OQ on NASDAQ Stock Exchange Global Market

1.42USD
2:29am IST
Change (% chg)

$0.09 (+6.77%)
Prev Close
$1.33
Open
$1.33
Day's High
$1.47
Day's Low
$1.31
Volume
679,413
Avg. Vol
971,311
52-wk High
$9.78
52-wk Low
$0.92

Latest Key Developments (Source: Significant Developments)

Corbus Pharmaceuticals Reports Third Quarter Financial Results And Provides Corporate Updates
Tuesday, 10 Nov 2020 

Nov 10 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES.Q3 LOSS PER SHARE $0.43.Q3 EARNINGS PER SHARE ESTIMATE $-0.42 -- REFINITIV IBES DATA.QTRLY REVENUE DECREASED BY ABOUT $1.4 MILLION FROM Q3 OF 2019 TO $1.2 MILLION.CORBUS PHARMACEUTICALS HOLDINGS- EXPECTS CASH & CASH EQUIVALENTS WITH PROCEEDS FROM MILESTONE PAYMENT TO FUND OPERATIONS BEYOND Q2 OF 2022.  Full Article

Corbus Pharmaceuticals Holdings Q2 Loss Per Share $0.52
Thursday, 6 Aug 2020 

Aug 6 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS SECOND QUARTER FINANCIAL RESULTS AND CORPORATE UPDATES.Q2 LOSS PER SHARE $0.52.Q2 EARNINGS PER SHARE ESTIMATE $-0.39 -- REFINITIV IBES DATA.CORBUS PHARMACEUTICALS - EXPECTS ITS CASH AND CASH EQUIVALENTS ON HAND AT JULY 28, 2020 TO FUND OPERATIONS INTO Q3 OF 202.  Full Article

Corbus Pharma Reports Q1 Financial Results
Monday, 11 May 2020 

May 11 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND CORPORATE UPDATES.Q1 LOSS PER SHARE $0.43.Q1 EARNINGS PER SHARE ESTIMATE $-0.40 -- REFINITIV IBES DATA.PHASE 1 TRIAL OF CRB-4001 REMAINS ON TRACK TO INITIATE IN Q3 OF 2020.CORBUS PHARMACEUTICALS - TOPLINE RESULTS FOR LENABASUM PHASE 3 RESOLVE-1 STUDY IN SYSTEMIC SCLEROSIS REMAIN ON SCHEDULE FOR SUMMER OF 2020.  Full Article

Corbus Have Entered Into Open Market Sale Agreement With Jefferies
Monday, 4 May 2020 

May 4 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS - HAVE ENTERED INTO OPEN MARKET SALE AGREEMENT WITH JEFFERIES LLC RELATING TO SHARES OF COMMON STOCK OFFERED BY THIS PROSPECTUS.CORBUS PHARMACEUTICALS - MAY OFFER, SELL SHARES OF COMMON STOCK OF UP TO $75 MILLION FROM TIME TO TIME.  Full Article

Corbus Pharmaceuticals Holdings Files For Mixed Shelf
Tuesday, 7 Apr 2020 

April 7 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS HOLDINGS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION -SEC FILING.  Full Article

Corbus Pharmaceuticals Reports Q4 Loss Per Share Of $0.41
Thursday, 12 Mar 2020 

March 12 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR-END 2019 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.41.Q4 EARNINGS PER SHARE ESTIMATE $-0.36 -- REFINITIV IBES DATA.CORBUS PHARMACEUTICALS - REVENUE FROM AWARDS & LICENSES WAS $2.6 MILLION FOR 3 MONTHS ENDED DEC 31, 2019, VERSUS $1.9 MILLION IN COMPARABLE PERIOD IN 2018.  Full Article

Corbus Pharma Holdings Says Public Offering Of 6.67 Mln Common Shares Priced At $6.00 Per Share
Friday, 7 Feb 2020 

Feb 7 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 6.67 MILLION COMMON SHARES PRICED AT $6.00PER SHARE.  Full Article

Corbus Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Friday, 7 Feb 2020 

Feb 6 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CORBUS PHARMA - INTENDS TO USE NET PROCEEDS OF UNDERWRITTEN OFFERING TO FUND DEVELOPMENT OF LENABASUM, CRB-4001, OTHER PRECLINICAL COMPOUNDS.  Full Article

Corbus Pharmaceuticals Q3 Loss Per Share $0.32
Thursday, 7 Nov 2019 

Nov 7 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS 2019 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CLINICAL AND CORPORATE UPDATES.Q3 LOSS PER SHARE $0.32.Q3 EARNINGS PER SHARE ESTIMATE $-0.38 -- REFINITIV IBES DATA.PHASE 2B STUDY OF LENABASUM FOR TREATMENT OF CYSTIC FIBROSIS ON TRACK FOR TOPLINE RESULTS IN SUMMER OF 2020.PHASE 1 FOR CRB-4001 IS ON TRACK FOR 2020.ENDED QUARTER WITH $54.8 MILLION IN CASH AND CASH EQUIVALENTS..  Full Article

Corbus Pharmaceuticals Q2 Earnings Per Share $0.03
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS 2019 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CLINICAL AND CORPORATE UPDATES.Q2 EARNINGS PER SHARE $0.03.Q2 EARNINGS PER SHARE ESTIMATE $-0.36 -- REFINITIV IBES DATA.CRB-4001 ON COURSE TO START PHASE 1 STUDY IN 2019 AS A CANDIDATE FOR NASH.  Full Article

BRIEF-Corbus Pharma Reports Last Subject Visit In Phase 2B Study Of Lenabasum For Treatment Of Cystic Fibrosis

* CORBUS PHARMACEUTICALS REPORTS LAST SUBJECT VISIT IN PHASE 2B STUDY OF LENABASUM FOR TREATMENT OF CYSTIC FIBROSIS